Nikhil Khushalani

Stories

HDAC inhibitor plus nivolumab cuts melanoma progression risk by 27% in Phase 3 trial

Presented the Phase 3 results at ESMO Congress 2026

Adding an oral histone deacetylase (HDAC) inhibitor to nivolumab cut the risk of melanoma progression or death by 27% in a 404-patient Phase 3 trial. Median progression-free survival was 11.7 months with the combination and 7.4 months with nivolumab alone, according to results presented at the European Society for Medical Oncology congress in Madrid.

Updated Oct 30

Notable Quotes

These results show, for the first time, that adding a selective HDAC inhibitor to anti-PD-1 therapy can improve treatment outcomes for patients with advanced melanoma.

from HDAC inhibitor plus nivolumab cuts melanoma progression risk by 27% in Phase 3 trial · Updated Oct 30

can certainly be considered a standard-of-care option for advanced unresectable melanoma, offering an advantage of oral dosing and potentially drug-specific dose attenuation for unique toxicities.

from HDAC inhibitor plus nivolumab cuts melanoma progression risk by 27% in Phase 3 trial · Updated Oct 30